CHICAGO, June 11, 2025 /PRNewswire/ -- The Global Home Healthcare Market share is projected to be valued at USD 420.79 billion in 2024 and reach USD...
Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs
Strasbourg, France and Charleroi, Belgium, June 11th 2025 – Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, announced today that it has closed an oversubscribed EUR 11.25 million Seed funding round. The round was co-led by Kurma Partners, WE Life Sciences and the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est and Sambrinvest. Elkedonia is bringing together stakeholders from across the European ecosystem, with headquarters in Strasbourg, France and an affiliate in Charleroi, Belgium.
EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that it will host a webcast to discuss its Q1 2025 business update and year-to-date highlights.
COLUMBIA, S.C., June 10, 2025 /PRNewswire/ -- Cattywampus, a delightfully quirky and mentally engaging word game, officially launches on the App Store and Google...
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology.
FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics...
Published in Cell Metabolism, the Phenomix and Mayo Clinic research shows the MyPhenome™ test can help providers guide obesity treatment by matching patients to GLP-1s...
Target Action (PDUFA) Date set for October 7, 2025
Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically...
SARASOTA, Fla., June 10, 2025 /PRNewswire/ -- World Precision Instruments (WPI), the global leader in transepithelial electrical resistance (TEER) technology, in collaboration with SynVivo, a...